Evidence map›Paper›PMID 27045265›Full record

ArticleThe journal of sexual medicine2016

Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease.

Faysal A Yafi, James Anaissie, Jonathan Zurawin, Suresh C Sikka, Wayne J G Hellstrom

Abstract read
PubMed Publisher
In one paragraph

Article in The journal of sexual medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Intralesional collagenaseInvestigative and clinical urology · 2022
    Trial
  3. Late-Onset Penile Fracture After CollagenaseCase reports in urology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Nonsurgical management of Peyronie's disease.Nature reviews. Urology · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Faysal A YafiDepartment of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
James AnaissieDepartment of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
Jonathan ZurawinDepartment of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
Suresh C SikkaDepartment of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
Wayne J G HellstromDepartment of Urology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address: hellst@tulane.edu.
Tulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIntralesional injection of collagenase clostridium histolyticum (CCH) for Peyronie's disease (PD) can result in serious adverse events such as hematoma formation and corporal rupture.

aimTo investigate the prevalence of complications from CCH and management trends among CCH prescribers.

methodsA survey was sent to all 693 members of the Sexual Medicine Society of North America (SMSNA) with valid email addresses. Responders were asked to participate if they were prescribers of CCH. Data regarding prescriber experience with CCH, procedural preferences, and rates and management strategies of complications were collected.

main outcome measureOne hundred SMSNA members completed the survey, with 36%, 23%, and 41% of responders having performed ≤10, 10 to 20, and >20 CCH injections, respectively.

resultsOf the responders, 94% reported hematomas in <25% of patients, with 63% preferring to observe and 37% treated with a combination of observation, application of a compressive dressing, and/or drainage of the hematoma. Corporal ruptures were encountered by 34% of physicians at a median of 5 days (0.5 to 30 days) from the last CCH injection. Rupture was located over the treated plaque in 84% of cases, and surgical intervention was the preferred management option by 67% of members. A distal circumcising degloving incision was used in 76% of cases, and 62% of responders reported the quality of tissue to be worse than would be expected with a non-CCH penile fracture. There were no significant differences in erectile function, ability to have intercourse, change in penile curvature, and patient satisfaction among patients who underwent surveillance vs surgery. One observed patient developed a penile abscess.

conclusionA wide variation exists among SMSNA members' strategies to prevent and manage complications of CCH. One in 3 prescribers reported encountering a corporal rupture during CCH therapy, and it is currently undetermined if there is a benefit of surgery vs conservative management.

Indexed as

Dose-Response Relationship, DrugHealth Care SurveysHematomaHumansInjections, IntralesionalMaleMicrobial CollagenaseMiddle AgedNorth AmericaPatient SatisfactionPenile IndurationPenisPractice Patterns, Physicians'RuptureTreatment OutcomeMicrobial CollagenaseCollagenase Clostridium HistolyticumCorporal FractureHematomaIntralesional Injection TherapyPeyronie’s DiseaseXiaflex

Identifiers

PMID27045265
OpenAlexW2306843518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.